Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients

Pharmacogenetics

Volumn 7, Issue 5, 1997, Pages 369-374

  Yasui, Norio ^a   Tybring, Gunnel ^b   Otani, Koichi ^a   Mihara, Kazuo ^a   Suzuki, Akihito ^a   Svensson, Jan Olof ^b   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2D6; Desmethylmianserin; Enantiomers; Mianserin; Thioridazine

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; DRUG METABOLITE; MIANSERIN; THIORIDAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACEMIC MIXTURE; STEADY STATE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DEPRESSION; ENZYME INHIBITORS; FEMALE; HOMOZYGOTE; HUMANS; JAPAN; MALE; MIANSERIN; STEREOISOMERISM; THIORIDAZINE;

EID: 0030772110     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199710000-00005     Document Type: Article

References (21)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC: American Psychiatric Association, 1994.
2. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP 3A isoforms. Br J Clin Pharmacol 1994: 38, 131-137.
3. Bertilsson L, Dahl M-L. Polymorphic drug oxidation. Relevance to the treatment of phychiatric disorders. CNS Drugs 1996: 5, 200-223.
4. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
5. Dahl M-L, Tybring G, Elwin C-E, Alm C, Andreasson K, Gyllenpalm M, Bertilsson L. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clin Pharmacol Ther 1994: 56, 176-183.
6. Delbressine LPC, Moonen MEG, Kaspersen FM, Jacobs PL, Wagenaars GL. Biotransformation of mianserin in laboratory animals and man. Xenobiotica 1992: 22, 227-236.
7. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
8. 1934 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990: 47, 994-1001.
9. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
10. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Söjqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra-rapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
11. Johansson I, Oscarson M, Yen QY, Bertilsson L, Söjqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450 locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994: 46, 452-459.
12. Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996: 278, 21-30.
13. Luurila H, Olkkola KT, Neuvonen PJ. Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacology & Toxicology 1996: 78, 117-122.
14. Montgomery S, McAuley R, Montgomery DB. Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single-time and divided daily dose regimens. Br J Clin Pharmacol 1978: 5 (Suppl. 1). 71-76S.
15. Nawishy S, Hathway N, Turner P. Interactions of anticonvulsant drugs with mianserin and nomifensine. Lancet 1981: 17, 871-872.
16. Otani K, Kaneko S, Sasa H, Kondo T, Fukushima Y. Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin? Human Psychopharmacol 1991: 6, 243-248.
17. Otani K, Sasa H, Kaneko S, Kondo T, Fukushima Y. Steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin. Ther Drug Monit 1995: 15, 113-117.
18. Pinder RM, van Delft AML. The potential therapeutic role of the enantiomers and metabolites of mianserin. Br J Clin Pharmacol 1983: 15 (Suppl. 1). 269-276S.
19. Spina E, Martines C, Caputi AP, Cabaleda J, Pinas B, Carrillo JA, Benitez J. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 1991: 41, 467-470.
20. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995: 5, 215-223.
21. Tybring G, Otani K, Kaneko S, Mihara K, Fukushima Y, Bertilsson L. Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. Ther Drug Monit 1995: 17, 516-521.